Drug Trial Radar · NCT07471217
[¹⁴C] Hydronidone Mass Balance Study
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Apr 17, 2026
Primary completion
May 6, 2026
Study completion May 6, 2026
Sponsor
- Lead sponsor
- Beijing Continent Pharmaceutical Co, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
According to the "Technical Guidelines for Radioactive Labeled Human Mass Balance Studies" issued by the NMPA, human mass balance studies are an important component of clinical pharmacology research for innovative drugs, and it is recommended that mass balance studies be conducted for all new molecular entities. Therefore, to further clarify the absorption, metabolism, and excretion characteristics of Hydronidone in the human body, a \[¹⁴C\] Hydronidone mass balance study is planned in Chinese healthy adult male participants. This study aims to reveal the pharmacokinetic characteristics of Hydronidone and provide a reference for the rational use of the drug.
Conditions
- Chronic Hepatitis B-related Liver Fibrosis
Interventions
[¹⁴C]HydronidoneDrug
Enrolled participants fasted for at least 10 hours prior to dosing. On the morning of Day 1 (D1), a single oral dose of \[¹⁴C\]Hydronidone suspension (containing approximately 90 mg/100 μCi of \[¹⁴C\]Hydronidone) was administered under fasting conditions, with approximately 240 mL of water used for preparation and administration. Except for the water used for dosing, no water was permitted within 1 hour before and after administration. Participants remained in the isotope ward of the study center from dosing until Day 9 (D9), which could be shortened or extended depending on whether the sample collection termination criteria were met."
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative radioactive recovery in excreta (urine and feces) per collection periodTime frame: within 9 days after dosing
- Cumulative total radioactive recovery in excreta (urine and feces)Time frame: within 9 days after dosing
- Pharmacokinetic parameters of total radioactivity in plasma : CmaxTime frame: within 9 days after dosing
- Pharmacokinetic parameters of total radioactivity in plasma : TmaxTime frame: within 9 days after dosing
- Pharmacokinetic parameters of total radioactivity in plasma : t1/2Time frame: within 9 days after dosing
- Pharmacokinetic parameters of total radioactivity in plasma : MRTTime frame: within 9 days after dosing
- Pharmacokinetic parameters of total radioactivity in plasma : AUCTime frame: within 9 days after dosing
- Whole blood ratio of total radioactivity concentrationTime frame: within 9 days after dosing
- plasma ratio of total radioactivity concentrationTime frame: within 9 days after dosing
- Percentage of unchanged drug relative to total radioactivity exposure in plasmaTime frame: within 9 days after dosing
- Percentage of unchanged drug in urine relative to the administered dose (%Dose)Time frame: within 9 days after dosing
- Percentage of unchanged drug in feces relative to the administered dose (%Dose)Time frame: within 9 days after dosing
- Identification of major metabolites in plasmaTime frame: within 9 days after dosing
- Identification of major metabolites in urineTime frame: within 9 days after dosing
- Identification of major metabolites in fecesTime frame: within 9 days after dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Gaobo Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.